<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="vivo when combined. These results demonstrate the value of loss-of-function" exact="screening" post="and pathway analysis for the rational identification of small"/>
 <result pre="is a mosquito-borne alphavirus that causes chikungunya fever, an acute" exact="infection" post="characterized by arthralgia and frequently complicated by chronic joint"/>
 <result pre="impact, little is known about the cell biology of CHIKV" exact="infection" post="and, as for all emerging infections, neither prophylactic nor"/>
 <result pre="the context of emerging infections, targeting host factors critical to" exact="infection" post="is a promising approach567. Indeed, this host-directed antiviral design"/>
 <result pre="We analyse the cellular pathways and factors necessary for CHIKV" exact="infection" post="and identify antiviral drugs with both in vitro and"/>
 <result pre="fluorescent protein (GFP) (CHIKV-GFP) in infected cells. At 18 h post" exact="infection" post="(p.i.), cells were fixed and analysed by automatic fluorescence"/>
 <result pre="RNA (vRNA) expression simultaneously (Supplementary Fig. 3a). Consistent with the" exact="screening" post="results, the expression of both the vRNA forms was"/>
 <result pre="druggable targets. In a first set of experiments, single-cycle CHIKV" exact="infection" post="was measured before or after viral entry (Fig. 5a)."/>
 <result pre="we were not able to precisely determine the step of" exact="infection" post="controlled by CLK1 (Supplementary Fig. 5a). Importantly, consistent with"/>
 <result pre="no detectable cell toxicity (Fig. 5j) when applied following 1-h" exact="infection" post="with wild-type CHIKV isolate C21. Of note, a delayed"/>
 <result pre="infection with wild-type CHIKV isolate C21. Of note, a delayed" exact="treatment" post="(6–8 h p.i.) had only a minor impact on vRNA"/>
 <result pre="on body weight gain (Fig. 6f,g; P=0.0133, two-sided t-test). Tivozanib" exact="treatment" post="also significantly reduced CHIKV viral load in different vital"/>
 <result pre="TOFA and pimozide combination resulted in increased inhibition of CHIKV" exact="infection" post="rate (5 μM each, interaction effect=0.44; lower=0.36; upper=0.54; P&amp;lt;0.001, two-factor"/>
 <result pre="Americas, still little is known regarding CHIKV cell biology. CHIKV" exact="infection" post="in human is associated with acute and chronic symptoms,"/>
 <result pre="cells (CRL-1573, ATCC-LGC) used for the genome-wide screening, the drug" exact="screening" post="and the drugs testing on different viral species were"/>
 <result pre="for the genome-wide screening, the drug screening and the drugs" exact="testing" post="on different viral species were cultured in DMEM (Life"/>
 <result pre="was determined by both GFP expression at 1 day post" exact="infection" post="and plaque formation at 7 days post infection of"/>
 <result pre="day post infection and plaque formation at 7 days post" exact="infection" post="of Vero E6 or HEK-293 cells. Virus stocks were"/>
 <result pre="or 10-day-old embryonated chicken eggs and used for experimentation. siRNA" exact="screening" post="HEK-293 cells were used for the screening because of"/>
 <result pre="for experimentation. siRNA screening HEK-293 cells were used for the" exact="screening" post="because of their concomitant permissiveness to CHIKV infection and"/>
 <result pre="for the screening because of their concomitant permissiveness to CHIKV" exact="infection" post="and to high-efficiency siRNA transfection. Transfections of siRNAs in"/>
 <result pre="were incubated at 37 °C and 5% CO2 for 72 h before" exact="infection" post="with 3.5 × 104 plaque-forming units (PFUs). At 18 h"/>
 <result pre="siRNAs with the indicated target sequence were included in all" exact="screening" post="plates as controls: siE1 5′-AACCGAUGAUAAGGCACGAAA-3′, siPLK1 5′-CACCAUAUGAAUUGUACAGAA-3′ and AllStars"/>
 <result pre="per gene were purchased from Ambion. The same transfection and" exact="screening" post="conditions were used as in the primary screen. Microarray"/>
 <result pre="CHIKV-GFP was performed 72 h post transfection at a multiplicity of" exact="infection" post="(MOI) of 3. Cells were lysed 18 h p.i. using"/>
 <result pre="Cells were lysed 18 h p.i. using Trizol (Invitrogen), followed by" exact="isolation" post="of RNA, which was subsequently subjected to microarray analysis."/>
 <result pre="activities of Rluc and Fluc were measured using a dual-luciferase" exact="detection" post="kit (Promega). For experiments in Fig. 3f, specific FASN,"/>
 <result pre="Consulting Kft, 1:200); incubation with primary antibodies was followed by" exact="treatment" post="with secondary antibodies: anti-rabbit antibodies conjugated with Alexa Fluor"/>
 <result pre="plasmids were kindly provided by K. Alitalo, Helsinki). Chemical compound" exact="screening" post="For screening of compounds with CHIKV, HEK-293 cells were"/>
 <result pre="kindly provided by K. Alitalo, Helsinki). Chemical compound screening For" exact="screening" post="of compounds with CHIKV, HEK-293 cells were pretreated on"/>
 <result pre="pipetting steps were performed as described above. To analyse primary" exact="infection" post="of herpes simplex type 1 strain KOS (HSV-1), cowpox"/>
 <result pre="and then inoculated with WSN at MOI 0.02. After 40 min," exact="infection" post="medium (DMEM supplemented with 0.2% BSA, 4 mM L-glutamine, antibiotics"/>
 <result pre="cells were cultivated for 6 h under normal culture conditions with" exact="infection" post="medium. Cells were stained for viral NP protein and"/>
 <result pre="were stained for viral NP protein and nuclei, and the" exact="infection" post="rate (that is, the rate of NP-positive cells) was"/>
 <result pre="by N-alkylation with propargyl bromide (step 3). In vitro drug" exact="testing" post="The following drugs were used following solubilization in DMSO:"/>
 <result pre="plates) were either treated 2 h before or 2 h after cell" exact="infection" post="with CHIKV C21 (MOI 40) and left until 8 h"/>
 <result pre="CHIKV C21 (MOI 40) and left until 8 h p.i. Viral" exact="infection" post="was quantified by flow cytometry measurement of the %"/>
 <result pre="cells. Equal amounts of supernatants (3 μl) from the 2 h post" exact="treatment" post="conditions were then measured for viral infectivity on Vero"/>
 <result pre="and flow cytometry For vRNA quantification, vRNA was extracted from" exact="infection" post="supernatants using the QIAamp Viral RNA Mini Kit (Qiagen),"/>
 <result pre="the analysis. The percentage of infected cells was used as" exact="infection" post="readout. Data were then normalized by setting the DMSO"/>
 <result pre="the DMSO condition as an arbitrary value of 100. Simultaneous" exact="detection" post="of FLT4 (clone 9D9F9, Biolegend, 356201, 1:50) and P-FLT4"/>
 <result pre="on 17 October 2014. Two different mouse models of CHIKV" exact="infection" post="were used for our studies: (i) the intradermal infection"/>
 <result pre="CHIKV infection were used for our studies: (i) the intradermal" exact="infection" post="model of neonatal mice, characterized by CHIKV dissemination through"/>
 <result pre="joints) and association with paralysis and death32; (ii) the footpad" exact="infection" post="model, characterized by a rapid local replication of CHIKV"/>
 <result pre="a rapid local replication of CHIKV at the site of" exact="infection" post="and by the induction of inflammation and footpad swelling363738."/>
 <result pre="with the microarray analysis, Dr Jens von Kries and his" exact="screening" post="unit, FMP, Berlin, Germany, for providing the enzymatic CLK1"/>
 <result pre="screening unit, FMP, Berlin, Germany, for providing the enzymatic CLK1" exact="screening" post="data, Isabella Gravenstein, David Manntz, Jörg Angermann, Christiane Dimmler"/>
 <result pre="virus infection. Science327, 198–201 (2010).19965718 LinK. &amp;amp; GallayP.Curing a viral" exact="infection" post="by targeting the host: the example of cyclophilin inhibitors."/>
 <result pre="Cell Rep.5, 1737–1748 (2013).24332855 VarbleA.et al.. An in vivo RNAi" exact="screening" post="approach to identify host determinants of virus replication. Cell"/>
 <result pre="BrassA. L.et al.. Identification of host proteins required for HIV" exact="infection" post="through a functional genomic screen. Science319, 921–926 (2008).18187620 KonigR.et"/>
 <result pre="(2009).19286138 LiQ.et al.. Integrative functional genomics of hepatitis C virus" exact="infection" post="identifies host dependencies in complete viral replication cycle. PLoS"/>
 <result pre="A pathogenic role for CD4+ T cells during Chikungunya virus" exact="infection" post="in mice. J. Immunol.190, 259–269 (2013).23209328 VanlandinghamD. L.et al.."/>
 <result pre="516–523 (2009).19572805 GlaskerS.et al.. Virus replicon particle based Chikungunya virus" exact="neutralization assay" post="using Gaussia luciferase as readout. Virol. J.10, 235 (2013).23855906"/>
 <result pre="J. Statist. Software12, 1–22 (2005). PonceM. A. &amp;amp; Erra-BalsellsR.Synthesis and" exact="isolation" post="of bromo-beta-carbolines obtained by bromination of beta-carboline alkaloids. J."/>
 <result pre="Bull.41, 1807–1811 (1993). PonceM. A., TarziO. I. &amp;amp; Erra-BalsellsR.Synthesis and" exact="isolation" post="of chloro-beta-carbolines obtained by chlorination of beta-carboline alkaloids in"/>
 <result pre="was performed as follows: assay development by P.B. and A.K.;" exact="screening" post="and data acquisition by A.K. and P.B.; validation and"/>
 <result pre="validation and data analysis: A.K. and M.M. CHIKV in vitro" exact="infection" post="and replication assays were performed by A.K., S.B., N.G."/>
 <result pre="were performed by A.K., S.B., N.G. and T.C. In vitro" exact="infection" post="and replication assays for all other viruses were performed"/>
 <result pre="Drug repurposing was performed by A.K. and M.M. (in vitro" exact="testing" post="and statistical association). Detailed characterization of hits was performed"/>
 <result pre="Primary screen for CHIKV host cell factors. (a) Outline of" exact="screening" post="procedure. (b) Heatmap of all identified proviral and antiviral"/>
 <result pre="treated 2 h before (solid lines) or 2 h after (dashed lines)" exact="infection" post="with CHIKV C21 (MOI 40) and left until 8 h"/>
 <result pre="an example). Equal amounts of supernatants from the 2 h post" exact="treatment" post="conditions were measured for viral infectivity on Vero cells"/>
 <result pre="the appearance of paralysis. (c) Experimental design of the intradermal" exact="infection" post="of the young mouse model used for tivozanib. (d–f)"/>
 <result pre="model used for tivozanib. (d–f) Effect of daily tivozanib (tivo)" exact="treatment" post="on C57BL/6 mouse survival, paralysis and body weight change"/>
 <result pre="weight curve. (h) CHIKV viral load measured 3 days post" exact="infection" post="in the indicated organs obtained from mice treated with"/>
 <result pre="for all data sets). (i,j) Experimental design of the footpad" exact="infection" post="of adult mice model used and viral titres measured"/>
 <result pre="n=11 for both data sets) or the corresponding vehicles before" exact="infection" post="with CHIKV C21 (103 PFU). Data in b,f and"/>
 <result pre="by flow cytometry. (d) Experimental design of the footpad CHIKV" exact="infection" post="model of adult mice used to measure the therapeutic"/>
 <result pre="considered for statistics). (e) Footpad swelling measured 4 days post" exact="infection" post="in mice treated as in d (n=11, 10, 12"/>
 <result pre="CHIKV replication and their respective molecular targets or pathways. CHIKV" exact="infection" post="and cell viability (WST-1) was measured in cells pretreated"/>
</results>
